Soligenix Inc
SNGX
NASDAQ
Biotechnology
$0.40
USD
+0.02 (+5.01%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.39M
Volume 321.2K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-10.24M
TTM
+1.2%
YoY
Operating Cash Flow
$-9.74M
TTM
-0.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.1 | 1.0 | 1.2 | 1.1 | 1.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.8 | 2.6 | 3.5 | 2.9 | 2.1 |
Operating Income | -2.8 | -2.6 | -3.5 | -2.9 | -2.1 |
EBITDA | -2.8 | -2.6 | -3.5 | -2.9 | -2.1 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | -0.0 | 0.1 |
Total Other Income / Expense | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 |
Income Before Income Taxes | -2.7 | -2.5 | -3.4 | -2.8 | -2.0 |
Income Taxes | 0.0 | 0.0 | -0.5 | 0.0 | 0.0 |
Net Income | -2.7 | -2.5 | -2.9 | -2.8 | -2.0 |
Consolidated Net Income / Loss | -2.7 | -2.5 | -2.9 | -2.8 | -2.0 |
Net Income Attributable to Common Shareholders | -2.7 | -2.5 | -2.9 | -2.8 | -2.0 |
Basic EPS | -$0.82 | -$0.58 | -$0.29 | -$0.28 | -$0.12 |
Diluted EPS | -$0.82 | -$0.58 | -$0.29 | -$0.28 | -$0.12 |
Basic Shares Outstanding | 3.3M | 4.3M | 10.1M | 10.2M | 16.0M |
Diluted Shares Outstanding | 3.3M | 4.3M | 10.1M | 10.2M | 16.0M |